In COPD, several TNF blocking agents have reached phase-II clinical trials, but these have been complicated by initial concerns related to increased incidence of cancer compared to the placebo control treatment arms (Rennard et al., 2007), which were later contested in a long-term follow-up analysis (Rennard et al., 2013). Here, TNF is linked to cancer.